PharmaMar begins trials of coronavirus drug on patients in Spain and France

Earlier this month, PharmaMar announced that in vitro studies results of Aplidin on the human coronavirus HCoV-229E, which has a multiplication and propagation mechanism very similar to Covid-19, had been positive.

It added that the results confirm the hypothesis that the “therapeutic target of Aplidin, which is EF1A, is key to the multiplication and spread of the virus.”

Now, according to a report on the El Español website, PharmaMar is testing its anti-coronavirus drug on humans in Spain and France.

In the case of Spain, testing of Aplidin on patients has begun in the haematology department at the Hospital Universitario 12 de Octubre, while trials are also taking place in France.

The report said the treatment acts against the EEF1A protein (present in human cells), thus cutting off the spread of the coronavirus.